Corbus Pharmaceuticals Holdings (CRBP) Amortization of Deferred Charges (2021 - 2022)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly Amortization of Deferred Charges of $189821.0 for Q4 2022, down 31.74% year-over-year from $278088.0 in Q4 2021, and up 3.16% quarter-over-quarter from $184004.0 in Q3 2022.
Corbus Pharmaceuticals Holdings (CRBP) Amortization of Deferred Charges (2021 - 2022) Analysis & Trends
Corbus Pharmaceuticals Holdings' Amortization of Deferred Charges history runs 2 years deep, the most recent figure standing at $189821.0 for Q4 2022.
- In Q4 2022, Amortization of Deferred Charges fell 31.74% year-over-year to $189821.0; the TTM figure through Dec 2022 stood at $703604.0 (changed N/A YoY), while the FY2022 annual figure was $724858.0, up 13.36% from the prior year.
- Amortization of Deferred Charges for Q4 2022 stood at $189821.0, up from $184004.0 in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $278088.0 in Q4 2021, with the low at $51691.0 in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Corbus Pharmaceuticals Holdings | 127.63 Mn | -35.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 189,821.00 |
| Dec 31, 2022 | 189,821.00 |
| Sep 30, 2022 | 184,004.00 |
| Sep 30, 2022 | 184,004.00 |
| Dec 31, 2021 | 278,088.00 |
| Dec 31, 2021 | 278,088.00 |
| Sep 30, 2021 | 51,691.00 |
| Sep 30, 2021 | 51,691.00 |